Background: ATIII is decreased in sepsis and/or shock and its baseline value correlates with mortality. The efficacy of ATIII therapy on mortality was assessed in a selected group of patients admitted to the intensive care unit (ICU) in a double-blind, randomized, multicenter study.
Methods: 120 patients admitted to the ICU with an ATIII concentration < 70% were randomized to receive ATIII (total dose 24000 units) or placebo treatment for 5 days; 56 patients had septic shock.
Results: ATIII concentrations in the treated group remained constant throughout the treatment period (range 97–102%). The Kaplan-Meier analysis showed no difference in overall survival between the two groups: 50 and 46 % for ATIII and placebo, respectively. Septic shock and hemodynamic support were unbalanced in the two groups at admission. Therefore the Cox analysis was carried out after adjusting for these two variables. Treatment with ATIII decreases the risk of death with an odds ratio (OR) of 0.56. Of the covariates analyzed, septic shock and the baseline multiple organ failure score were negatively associated with survival and plasma activity level was positively associated with survival with an OR of 0.97 for each 1 % increase in the ATIII plasma concentration at baseline.
Conclusions: The results of ATIII treatment in this population of patients suggests that replacement therapy reduces mortality in the subgroup of septic shock patients only.
Buller HR, Ten Cate JW (1989) Acquired antithrombin III deficiency: laboratory diagnosis, incidence, clinical implications and treatment with antithrombin III concentrate. Am J Med 87 [Suppl 3B]: 44s-48sPubMedCrossRefGoogle Scholar
Blauhut B, Necek S, Vinazzer H, Bergmann H (1982) Substitution therapy with an antithrombin III concentrate in shock and DIC. Thromb Res 27: 271–278PubMedCrossRefGoogle Scholar
Hesselvik JF, Malm J, Dahlback B, Blomback M (1991) Protein C, protein S and C4b-binding protein in severe infection and septic shock. Thromb Hemost 62: 126–129Google Scholar
Fourrier F, Chopin C, Goudemand J, Hendrycx S, Caron C, Rime A, Marey A, Lestavel P (1992) Septic shock, multi organ failure and disseminated intravascular coagulation. Compared pattern of ATIII, protein C, protein S deficiencies. Chest 101: 816–823PubMedCrossRefGoogle Scholar
Blauhut B, Kramar H, Vinazzer H, Bergmann H (1984) Substitution of antithrombin III in shock and DIC: a randomized study. Thromb Res 39: 81–89CrossRefGoogle Scholar
Wilson RF, Mammen EF, Robson MC, Heggers JP, Soullier G, DePoli PA (1986) Antithrombin, prekallikrein and fibronectin levels in surgical patients. Arch Surg 121: 635–643PubMedGoogle Scholar
Sandset PM, Roise O, Aasen AO, Abildgaard U (1989) Extrinsic pathway inhibitor in post operative post traumatic septicaemia: increased levels in fatal cases. Hemostasis 19: 189–195Google Scholar
Hesselvik JF, Blomback M, Brodin B, Maller R (1989) Coagulation, fibrinolysis and kallikrein systems in sepsis: relation to outcome. Crit Care Med 17: 724–733PubMedGoogle Scholar
Lammle B, Tran TM, Ritz R, Duckert F (1984) Plasma prekallikrein, factor XII, ATIII, C1-inhibitor and α2 macroglobulin in critically ill patients with suspected disseminated intravascular coagulation (DIC). Am J Clin Pathol 82: 396–404PubMedGoogle Scholar
Maki M, Terao T, Ikenoue T, Takemura T, Sekiba K, Shirakawa K, Soma H (1987) Clinical evaluation of antithrombin concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Gynecol Obstet Invest 23: 230–240PubMedGoogle Scholar
Vinazzer H (1989) Therapeutic use of antithrombin III in shock and disseminated intravascular coagulation. Semin Thromb Hemost 15: 347–352PubMedCrossRefGoogle Scholar
Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J (1993) Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 104: 882–888PubMedCrossRefGoogle Scholar
Lamy M, Eisele B, Keinecke H-O, Delvos U, Thijs LG (1996) Antithrombin III in patients with severe sepsis. A randomised, placebo-controlled, double-blind multicenter trial. Abstr.9th European Congress on Intensive Care Medicine, pp 385–390, GlasgowGoogle Scholar
Knaus WA, Draper EA, Wagner DP, Zimmerman JE (1985) APACHE II: a severity of disease classification system. Crit Care Med 13: 818–829PubMedCrossRefGoogle Scholar
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis (1992). Crit Care Med 20: 864–874CrossRefGoogle Scholar
La Gall JR, Loirat P, Alperovith A, Glaser P, Granthil C, Mathieu D, Mercier P, Thomas R, Villers D (1984) A simplified acute physiology score for ICU patients. Crit Care Med 12: 975–977PubMedCrossRefGoogle Scholar
Lechner K, Kyrie PA (1995) Antithrombin III concentrates — are they clinically useful? Thromb Haemost 73: 340–348PubMedGoogle Scholar
Salvo I, DeCian W, Musicco M, Langer M, Piadena R, Wolfler A, Mowtani C, Magni E (1995) The Italian SEPSIS study: preliminary results on incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 21: S244-S249PubMedCrossRefGoogle Scholar
Dickneite G, Paques EP (1993) Reduction of mortality with antithrombin III in septicaemia rats: a study of Klebsiella pneumoniae induced sepsis. Thromb Haemost 69: 98–102PubMedGoogle Scholar
Kessler CM, Tang ZC, Jacobs HM, Szymanski LM (1997) The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: substantial reduction in mortality and morbidity. Blood 89: 4393–4401PubMedGoogle Scholar
Jochum M (1995) Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines and soluble adhesion molecules in acute inflammation Semin Hematol 32: 19–32PubMedGoogle Scholar
Mesters RM, Mannucci PM, Coppola R, Keller T, Ostermann H, Kienast J (1996) Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients. Blood 88: 881–886PubMedGoogle Scholar